Why ePROs In Oncology Are Perfect For Capturing The Patient's Voice

In recent years, oncology trials have surged, yet the integration of electronic patient-reported outcomes (ePROs) remains surprisingly low, with only 8.3% of FDA-approved oncology drugs from 2010 to 2020 incorporating them. Despite FDA initiatives, such as "Project Patient Voice," aimed at promoting ePROs to enhance the understanding of patient experiences and quality of life during treatment, their adoption in clinical trials is lagging.

ePROs enable patients to directly report their symptoms, side effects, and overall well-being, offering critical insights that can inform treatment discussions between patients and healthcare providers. While many patients are open to participating in surveys, ePROs can alleviate survey fatigue, making data collection more feasible. By incorporating ePROs into oncology trials, researchers can ultimately improve clinical trial designs and cancer therapies that prioritize both survival and quality of life for patients.